|Bid||10.87 x 900|
|Ask||10.94 x 1200|
|Day's Range||10.82 - 11.18|
|52 Week Range||9.22 - 53.75|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 10, 2021 - Aug. 16, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.88|
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
PHILADELPHIA, PA / ACCESSWIRE / June 2, 2021 / Kaskela Law LLC announces that it is investigating Immunovant, Inc. (Nasdaq: IMVT) on behalf of the Company's stockholders.
Immunovant's (IMVT) earnings beat estimates in fourth-quarter fiscal 2021. Focus remains on lead pipeline candidate IMVT-1401. Stock falls.